Evidence map›Paper›PMID 37645746›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Genetic evidence for serum amyloid P component as a drug target for treatment of neurodegenerative disorders.

A Floriaan Schmidt, Chris Finan, Sandesh Chopade, Stephan Ellmerich, Martin N Rossor, Aroon D Hingorani, Mark B Pepys

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

A Floriaan SchmidtInstitute of Cardiovascular Science, Faculty of Population Health, University College London, London, United Kingdom.
Chris FinanInstitute of Cardiovascular Science, Faculty of Population Health, University College London, London, United Kingdom.
Sandesh ChopadeInstitute of Cardiovascular Science, Faculty of Population Health, University College London, London, United Kingdom.
Stephan EllmerichWolfson Drug Discovery Unit, Division of Medicine, University College London, London, United Kingdom.
Martin N RossorUCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, United Kingdom.
Aroon D HingoraniInstitute of Cardiovascular Science, Faculty of Population Health, University College London, London, United Kingdom.
Mark B PepysWolfson Drug Discovery Unit, Division of Medicine, University College London, London, United Kingdom.
British Heart Foundation · GBUniversity College London · GBUtrecht University · NLNational Hospital for Neurology and Neurosurgery · GB

Funding

Bioinformatics Strategies for Genome-Wide Association StudiesR01LM010098 · NLM · UNIVERSITY OF PENNSYLVANIA · PI MOORE, JASON H., WILLIAMS, SCOTT MATTHEW · 2009 to 2023
$5.1M
British Heart Foundation PG/22/10989Medical Research Council MR/V033867/1NLM NIH HHS R01 LM010098
6 · The paper itself

Abstract

The direct causes of neurodegeneration underlying Alzheimer's disease (AD) and many other dementias, are not known. Here we identify serum amyloid P component (SAP), a constitutive plasma protein normally excluded from the brain, as a potential drug target. After meta-analysis of three genome-wide association studies, comprising 44,288 participants,

Indexed as

Alzheimer’s diseasedementiagenome-wide association studyLewy body dementiaMendelian randomizationmiridesapneurodegenerationserum amyloid P component

Identifiers

PMID37645746
PMCPMC10462209
OpenAlexW4385952758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.